CKD732

angiogenesis inhibitor

Also Known As:

(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate; CKD-732; O-(4-dimethylaminoethoxycinnamoyl)fumagillol; beloranib

Networked: 20 relevant articles (2 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Malloy, Jaret: 3 articles (01/2018 - 01/2017)
2.	Hughes, Thomas E: 2 articles (01/2018 - 12/2017)
3.	Proietto, Joseph: 2 articles (01/2018 - 01/2017)
4.	Taylor, Kristin: 2 articles (01/2018 - 12/2017)
5.	Zhuang, Dongliang: 2 articles (01/2018 - 12/2017)
6.	Abuzzahab, M Jennifer: 2 articles (12/2017 - 01/2017)
7.	Kim, Dennis D: 2 articles (12/2017 - 01/2017)
8.	Hughes, T E: 2 articles (06/2015 - 09/2013)
9.	Kim, D D: 2 articles (06/2015 - 09/2013)
10.	Marjason, J: 2 articles (06/2015 - 09/2013)

Related Diseases

1.	Obesity 01/01/2017 - "A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity." 01/01/2014 - "Beloranib is a prototype MetAP2 inhibitor, and currently in advanced clinical trials for the treatment of obesity. " 12/01/2015 - "In view of regulators' caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. " 06/01/2015 - "To assess the efficacy, safety and tolerability of beloranib treatment for obesity. " 03/01/2015 - "Aspergillus, angiogenesis, and obesity: the story behind beloranib."
2.	Overweight 01/01/2023 - "According to the results of this NMA, semaglutide seems to be an effective treatment option for both men and women, whereas beloranib appears to be particularly effective for women with obesity and overweight, but its production has been stopped since 2016 and is not available."
3.	Weight Loss (Weight Reduction) 06/01/2015 - "In this 12-week phase II study, beloranib produced clinically and statistically significant weight loss and corresponding improvements in cardiometabolic risk factors. " 01/01/2017 - "Weight loss continued through the 8 weeks in patients randomized to beloranib (mean -6.2 [-8.2, -4.1] kg). " 01/01/2017 - "The model was externally evaluated with data from the investigational compound beloranib, for which longer term weight loss could be successfully predicted based on early response data. " 06/01/2015 - "At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5 ± 0.5, -6.9 ± 0.6 and -10.9 ± 1.1 kg for the 0.6, 1.2 and 2.4 mg beloranib doses, respectively, compared with -0.4 ± 0.4 kg with placebo (all p < 0.0001 vs placebo). " 06/01/2015 - "Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial."
4.	Neoplasms (Cancer) 10/01/2010 - "Using a dose escalation schedule, 19 patients with refractory solid tumors were enrolled at dose levels of CKD-732 ranging from 1 to 15 mg/m(2) given twice weekly for 2 weeks followed by a 1-week rest. " 10/01/2010 - "A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer." 03/01/2015 - "Beloranib, a fumagillin analog that is an angiogenesis inhibitor and associated with decreased adiposity in animals, has been studied in phase I clinical trials for cancer. " 03/10/2005 - "In our study reported here, the effects of 4 highly potent methionine aminopeptidase 2 (MetAP2) inhibitors, IDR-803, IDR-804, IDR-805 and CKD-732 (designed by structure-based molecular modeling), on angiogenesis and tumor growth were assessed. "
5.	Hyperphagia (Overeating) 12/01/2017 - "Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity." 12/01/2017 - "MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia-related behaviours and weight loss in participants with PWS. " 01/01/2017 - "Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity." 01/21/2023 - "The status of clinical trials with existing results for the management of obesity and hyperphagia in PWS will be discussed in this review, including treatments such as beloranib, setmelanotide, a diazoxide choline controlled-release tablet (DCCR), an unacylated ghrelin analogue, oxytocin and related compounds, glucagon-like peptide 1 receptor agonists, surgical intervention, and transcranial direct-current stimulation."

Related Drugs and Biologics

1.	semaglutide
2.	ZGN-1061
3.	Ghrelin
4.	methionine aminopeptidase 2
5.	Angiogenesis Inhibitors
6.	setmelanotide
7.	Tablets
8.	Suspensions
9.	Oxytocin (Pitocin)
10.	Diazoxide (Hyperstat)

Related Therapies and Procedures

1.	Transcranial Direct Current Stimulation
2.	Drug Therapy (Chemotherapy)